who

ARNAY Sciences is a life science research practice focusing on the chemical engineering of DNA and RNA for RNA Therapeutics.

ARNAY was established by Sudhir Agrawal, who, over the last three decades, has been active in research in this field, both in academia and industry.

Home - Life Science Research
What

ARNAY addresses broadly applicable components of RNA therapeutics, including sequence, chemistry, and delivery. ARNAY makes these components available to researchers and entrepreneurs for creating RNA Therapeutics.

What

ARNAY addresses broadly applicable components of RNA therapeutics, including sequence, chemistry, and delivery. ARNAY makes these components available to researchers and entrepreneurs for creating RNA Therapeutics.

how

New class of drugs

Recently, a new class of drugs composed of short RNA and DNA has been approved. These drugs, called antisense and siRNA, bind to disease-associated aberrant RNA in the body and modulate the translation of disease-associated proteins. Based on the genetic sequence of a specific RNA, a complementary short RNA and DNA can be created to hybridize to the targeted RNA.

Our history

Lessons learned

While this seems simple, lessons have been learned over four decades on providing drug-like properties to these short pieces of RNA and DNA. The important factors of success lie in the nucleotide sequence and the chemistry used to imbue the sequence with drug-like properties. While the antisense sequence is complementary to the RNA, challenges arise when the sequence also acts as a pathogen-associated molecular pattern and triggers unintended immune responses. Chemical Engineering of DNA and RNA has been shown to modulate immune responses.

From Idea to Reality

Chemistry enabled success

Once an appropriate sequence is selected, the chemistry that provides the selected RNA drug-like properties must be applied. For example, gapmer chemistry, which I developed in the early 90s, is now widely used in antisense drug candidates that have been approved.

About

Chemical Engineering of Oligonucleotides for therapeutics

ARNAY continues fine-tuning sequences and engineering novel chemistry to create potent and safe drugs. With three decades of insight, ARNAY has designed novel chemical structures that significantly increase the potency and specificity of RNA therapeutic candidates. These chemical structures have broad applicability in developing RNA therapeutics and immunotherapy. 

From Idea to Reality

Chemistry enabled success

Once an appropriate sequence is selected, the chemistry that provides the selected RNA drug-like properties must be applied. For example, gapmer chemistry, which I developed in the early 90s, is now widely used in antisense drug candidates that have been approved.

Home - From Idea to reality - background
Team

Chemical Engineering of Oligonucleotides for therapeutics

ARNAY continues fine-tuning sequences and engineering novel chemistry to create potent and safe drugs. With three decades of insight, ARNAY has designed novel chemical structures that significantly increase the potency and specificity of RNA therapeutic candidates. These chemical structures have broad applicability in developing RNA therapeutics and immunotherapy. ARNAY has entered into a collaboration and licensing agreement with Alloy Therapeutics to advance this platform further and to be used by researchers and entrepreneurs to create RNA therapeutics.

Looking to delve deeper into the science behind ARNAY Sciences?

Explore our collection of related articles and resources that validate the groundbreaking work we do in the field of RNA therapeutics. Our commitment to scientific excellence is evident in the research and discoveries we’ve made over the years.

Home - Get in touch background
Get in touch

Ready to explore the possibilities of RNA therapeutics or have questions about our research?

Contact Sudhir Agrawal, the visionary behind ARNAY Sciences. Whether you’re an established researcher, entrepreneur, or simply curious about the potential of RNA engineering, Sudhir and our team are here to assist you in realizing your goals and advancing the field of life sciences.

Looking to delve deeper into the science behind ARNAY Sciences?

Explore our collection of related articles and resources that validate the groundbreaking work we do in the field of RNA therapeutics. Our commitment to scientific excellence is evident in the research and discoveries we’ve made over the years.

Get in touch

Ready to explore the possibilities of RNA therapeutics or have questions about our research?

who

ARNAY Sciences is a life science research practice focusing on the chemical engineering of DNA and RNA for RNA Therapeutics.

ARNAY was established by Sudhir Agrawal, who, over the last three decades, has been active in research in this field, both in academia and industry.

Home - Life Science Research
What

ARNAY addresses broadly applicable components of RNA therapeutics, including sequence, chemistry, and delivery. ARNAY makes these components available to researchers and entrepreneurs for creating RNA Therapeutics.

who

ARNAY Sciences is a life science research practice focusing on the chemical engineering of DNA and RNA for creating RNA Therapeutics.

ARNAY was established by Sudhir Agrawal, who, over the last three decades, has been active in research in this field, both in academia and industry.

Article

A recent article describing developments at Arnay Sciences.

What

ARNAY addresses broadly applicable components of RNA therapeutics, including sequence, chemistry, and delivery. ARNAY makes these components available to researchers and entrepreneurs for creating RNA Therapeutics.

how

New class of drugs

Recently, a new class of drugs composed of short RNA and DNA has been approved. These drugs, called antisense and siRNA, bind to disease-associated aberrant RNA in the body and modulate the translation of disease-associated proteins. Based on the genetic sequence of a specific RNA, a complementary short RNA and DNA can be created to hybridize to the targeted RNA.

Our history

Lessons learned

While this seems simple, lessons have been learned over four decades on providing drug-like properties to these short pieces of RNA and DNA. The important factors of success lie in the nucleotide sequence and the chemistry used to imbue the sequence with drug-like properties. While the antisense sequence is complementary to the RNA, challenges arise when the sequence also acts as a pathogen-associated molecular pattern and triggers unintended immune responses. Chemical Engineering of DNA and RNA has been shown to modulate immune responses.

From Idea to Reality

Chemistry enabled success

Once an appropriate sequence is selected, the chemistry that provides the selected RNA drug-like properties must be applied. For example, gapmer chemistry, which I developed in the early 90s, is now widely used in antisense drug candidates that have been approved.

About

Chemical Engineering of Oligonucleotides for therapeutics

ARNAY continues fine-tuning sequences and engineering novel chemistry to create potent and safe drugs. With three decades of insight, ARNAY has designed novel chemical structures that significantly increase the potency and specificity of RNA therapeutic candidates. These chemical structures have broad applicability in developing RNA therapeutics and immunotherapy. 

From Idea to Reality

Chemistry enabled success

Once an appropriate sequence is selected, the chemistry that provides the selected RNA drug-like properties must be applied. For example, gapmer chemistry, which I developed in the early 90s, is now widely used in antisense drug candidates that have been approved.

Home - From Idea to reality - background
Team

Chemical Engineering of Oligonucleotides for therapeutics

ARNAY continues fine-tuning sequences and engineering novel chemistry to create potent and safe drugs. With three decades of insight, ARNAY has designed novel chemical structures that significantly increase the potency and specificity of RNA therapeutic candidates. These chemical structures have broad applicability in developing RNA therapeutics and immunotherapy. ARNAY has entered into a collaboration and licensing agreement with Alloy Therapeutics to advance this platform further and to be used by researchers and entrepreneurs to create RNA therapeutics.

Looking to delve deeper into the science behind ARNAY Sciences?

Explore our collection of related articles and resources that validate the groundbreaking work we do in the field of RNA therapeutics. Our commitment to scientific excellence is evident in the research and discoveries we’ve made over the years.

Home - Get in touch background
Get in touch

Ready to explore the possibilities of RNA therapeutics or have questions about our research?

Contact Sudhir Agrawal, the visionary behind ARNAY Sciences. Whether you’re an established researcher, entrepreneur, or simply curious about the potential of RNA engineering, Sudhir and our team are here to assist you in realizing your goals and advancing the field of life sciences.

Looking to delve deeper into the science behind ARNAY Sciences?

Explore our collection of related articles and resources that validate the groundbreaking work we do in the field of RNA therapeutics. Our commitment to scientific excellence is evident in the research and discoveries we’ve made over the years.

Get in touch

Ready to explore the possibilities of RNA therapeutics or have questions about our research?